AZ fills top R&D spot with Genentech's Bohen; Regulators OK Pfizer's Hospira deal;

> Genentech's Sean Bohen will take up the post as AstraZeneca's ($AZN) R&D chief. More

> Regulators have approved Pfizer's ($PFE) Hospira ($HSP) buyout deal, pending the divestiture of some sterile injectable drugs. Report

> Bayer HealthCare has launched a digital healthcare accelerator in Berlin. Report

> South Korean pharmaceutical companies are beefing up their presence in the global healthcare industry through global partnerships. More

> Merck KGaA will close down Bangalore GeNei, a company it acquired in 2009 to boost its capabilities in design, development and production of biological research products. More

And Finally... Google's ($GOOG) Life Sciences division is developing a wearable blood glucose monitor that could revolutionize diabetic care and treatment. Report

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.